FDA Clears New AI-Powered MRI System from Fujifilm
The Echelon Synergy MRI system reportedly uses deep learning technology to accelerate image acquisition and enhance image quality.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Echelon Synergy magnetic resonance imaging (MRI) system, which combines artificial intelligence (AI) enhancements for image acquisition and quality with improved radiology workflow efficiencies.
The Echelon Synergy MRI system utilizes proprietary Deep Learning Reconstruction technology to improve the quality of MRI scans and the speed of acquiring the images, according to Fujifilm Healthcare Americas Corporation, the manufacturer of the new 1.5 Tesla MRI system.
One key benefit of the Echelon Synergy MRI system is the AutoExam One Touch, which allows automated workflows for brain and knee MRI exams.
In order to facilitate improved patient comfort, Fujifilm said the Echelon Synergy system offers reduced acoustic noise through SoftSound™ gradient technology as well as a 70 cm-wide bore and 62 cm-wide table that can accommodate patients weighing up to 550 pounds.
“Fujifilm is committed to delivering medical advancements focused on enhancing the patient’s experience while streamlining the workflow for today’s busy imaging providers,” noted Shawn Etheridge, the executive director of modality solutions for Fujifilm Healthcare Americas Corporation.
“Echelon Synergy is designed to facilitate optimal comfort and help alleviate anxiety with its large bore and wide patient table. Alleviating any patient anxiety not only helps to enhance the patient experience, but could also improve a radiologist’s workflow, as the less nervous a patient, the more efficient and quickly the scan will get done.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
